Orion Corporation and Newel Health (?Newel?) have entered into a license agreement regarding ODD-403 (?Rohkea?), a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the agreement, Newel will have the exclusive global rights to develop, manufacture and commercialise ODD-403. Orion is entitled to receive royalty from the sales of the product as well as sales milestone payments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.68 EUR | -0.31% | +7.73% | -9.14% |
Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
Apr. 25 | Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.14% | 5.38B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- ORNBV Stock
- News Orion Oyj
- Orion Corporation and Newel Health Enter into Licensing Agreement for Digital Therapeutic(DTx) ODD-403 (?Rohkea?) in pain